COMP <GO>
TWST vs MRK // NET PROFIT MARGIN
Twist Bioscience Corporation (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: TWST 4
— MRK 10
▲ NET PROFIT MARGIN LEADER: MRK
LAST: $152.78 (-11.92%) • MKT CAP: $11.50B
net-margins
-2.40%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
net-margins
28.10%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TWST VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TWST | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 94.20% | 74.80% | +19.40 | TWST | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -11.70% | 20.70% | -32.40 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.66% | 3.42% | -4.08 | MRK | /fcf-yield <GO> |
| Operating Margin | -4.20% | 34.30% | -38.50 | MRK | /operating-margins <GO> |
| Net Profit Margin ACTIVE | -2.40% | 28.10% | -30.50 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 16.50% | 1.30% | +15.20 | TWST | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 5.19 | +20.81 | TWST | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.80% | 6.60% | +0.20 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.2 | 56.9 | -7.62 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.98 | 0.92 | +0.06 | TWST | /macro-sensitivity <GO> |
| Forward P/E Multiple | 21.0x | 18.4x | +2.60 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $11.50B | $361.02B | -$349.52B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TWST REV | MRK REV | TWST GROSS % | MRK GROSS % | TWST FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $65.01B | — | 74.8% | -$75.6M | $12.36B |
| FY 2024 | $0 | $64.17B | — | 76.3% | -$69.2M | $18.10B |
| FY 2023 | $0 | $60.12B | — | 44.0% | -$142.5M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TWST // BETA 0.98
MRK // BETA 0.92